Free Trial
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel
NASDAQ:VIR

Vir Biotechnology Q3 2026 Earnings Date & Estimates

Vir Biotechnology logo
$11.70 +0.58 (+5.22%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$11.62 -0.08 (-0.67%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vir Biotechnology in Q3 2026

Vir Biotechnology is expected to post earnings of -$0.7393 per share on revenue of $0.87 million. In the same quarter a year earlier Vir Biotechnology reported -$1.17 per share on revenue of $0.24 million. Vir Biotechnology last reported on August 5, 2026, posting $0.47 per share and beating the $0.3326 consensus estimate. Vir Biotechnology has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7393
Expected Revenue
$0.87 million
Prior-Year EPS
-$1.17
Prior-Year Revenue
$0.24 million
Expected Revenue Growth
+260.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.47 (Beat by +$0.1374)
Last Quarter Revenue
$238.95 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Vir Biotechnology Q3 2026 Earnings FAQ

Vir Biotechnology (NASDAQ:VIR) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Vir Biotechnology's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Vir Biotechnology to post earnings of -$0.7393 per share for Q3 2026.

The consensus revenue estimate for Vir Biotechnology is $0.87 million for Q3 2026.

Vir Biotechnology Earnings Headlines

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - What's Next?
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105412
Vir Biotechnology stock hits 52-week high at 11.96 USD
October 9 at 6:47 PM  |  ca.investing.comhttps://ca.investing.com/news/stock-market-news/vir-biotechnology-stock-hits-52week-high-at-1196-usd-93CH-4873947
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.tc pixel
 |  Traders Agency (Ad)
Vir Biotechnology, Inc. Announces Appointment of David Liu as Executive Vice President and Chief Medical Officer, Effective October 12, 2026
October 9 at 8:46 AM  |  marketscreener.comM
Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of ...
October 9 at 8:46 AM  |  marketscreener.comM
Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer
October 9 at 8:46 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-apos-vir-5500-134318305.html
See More Vir Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vir Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vir Biotechnology and other key companies, straight to your email.

About Vir Biotechnology

Vir Biotechnology (NASDAQ:VIR) is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir’s research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections. Vir also has pursued vaccine and immune-based approaches through collaborations with external research and pharmaceutical partners.

Founded in 2016 and headquartered in San Francisco, Vir gained broad recognition through its collaboration with GlaxoSmithKline to develop sotrovimab, an antibody treatment for COVID-19 that received emergency and other regulatory authorizations during the pandemic. The company’s work is directed primarily toward global infectious-disease needs, with clinical development and research activities conducted through international partnerships and study sites.

View Vir Biotechnology Profile
Earnings Tools